Results 31 to 40 of about 2,912 (169)

Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]

Expert Review of Anti-infective Therapy, 2020
infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs. Meropenem-vaborbactam (M/V) is a combination of a group 2 carbapenem with a novel cyclic boronic acid-based β-lactamase inhibitor which has shown good efficacy against KPC ...
Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M   +3 more
openaire   +3 more sources

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

Journal of Global Antimicrobial Resistance, 2023
: Objectives: Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (
A. Oliva, D. Al Ismail, G. Arcari, MC. Miele, E. Casali, F. Sacco, L. Volpicelli, M. De Angelis, M.T. Mascellino, F. Cancelli, G. Raponi, A. Carattoli, M Venditti   +12 more
doaj   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

Infection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R   +3 more
doaj  

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

Expert Review of Anti-infective Therapy, 2022
The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin. The search terms ‘meropenem-vaborbactam’ or RX7009 for the years 2006 until 2021 were used.
Mouktaroudi, M., Kotsaki, A., Giamarellos-Bourboulis, E.J.   +2 more
openaire   +3 more sources

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials. Intravenous meropenem/vaborbactam (Vabomere™) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis ...
openaire   +2 more sources

Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. [PDF]

Infect Dis Ther
Among drug-resistant bacteria, carbapenem-resistant Enterobacterales (CRE) are a major clinical challenge with limited options for treatment. In the last several years, new treatment options have emerged for CRE, including meropenem-vaborbactam (MVB).
Bassetti M, Giacobbe DR, Vena A, Poulakou G, Rossolini GM, Soriano A, Nicolau DP.   +6 more
europepmc   +6 more sources

Correlation between Mechanism of Carbapenem Resistance and in vitro Efficacy of Ceftazidime-Avibactam and Meropenem-Vaborbactam on Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa

Pakistan Armed Forces Medical Journal, 2022
Objective: To determine the mechanism of Carbapenem resistance, type of Carbapenemase produced and in vitro efficacy of Ceftazidime-Avibactam (CAZ-AVI) and Meropenem-Vaborbactam (MEV) against Carbapenem-resistant Enterobacterales and in vitro efficacy ...
Fatima Ali, Irfan Ali Mirza, Hafsa Waseem, Umer Khursheed, Humaira Zafar, Maryiam Sarwar   +5 more
doaj   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin

Journal of Global Antimicrobial Resistance
Objective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli, Sara Cairoli, Dania Al Ismail, Floriana Baisi, Federica Sacco, Bianca Maria Goffredo, Mario Venditti, Alessandra Oliva   +7 more
doaj   +1 more source